Osteoarthritis Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Osteoarthritis Pain Pipeline Drugs Market Report Overview
Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis Pain – Drugs In Development, 2022, provides an overview of the Osteoarthritis Pain (Central Nervous System) pipeline landscape.
Osteoarthritis pain pipeline drugs market is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. If the condition worsens, it leads to rubbing of the bones against each other causing even more pain and loss of movement. Risk factors are age, joint injury, obesity and heredity. Treatment includes weight control, exercise and medications.
Report Highlights
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis Pain – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Osteoarthritis Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteoarthritis Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 9, 32, 10, 1, 16, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Osteoarthritis Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Osteoarthritis Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Osteoarthritis Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Osteoarthritis Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis Pain (Central Nervous System)
Reasons to Buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Osteoarthritis Pain (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Osteoarthritis Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Achelios Therapeutics Inc
Adolore Biotherapeutics Inc
AlzeCure Pharma AB
Ampio Pharmaceuticals Inc
Andros Pharmaceuticals Co Ltd
AntalGenics SL
Antibe Therapeutics Inc
Apimeds Inc
APT Therapeutics Inc
Aquilus Pharmaceuticals Inc
AstraZeneca Plc
Avecho Biotechnology Ltd
Axsome Therapeutics Inc
Beijing Tide Pharmaceutical Co Ltd
BioTissue Inc
BriOri BioTech Inc
Centrexion Therapeutics Corp
Chromocell Corp
Concentric Analgesics Inc
Daewoong Pharmaceutical Co Ltd
Eccogene (Shanghai) Co Ltd
Eli Lilly and Co
Elite Pharmaceuticals Inc
Ensign Pharmaceutical Inc
Eupraxia Pharmaceuticals Inc
EyePoint Pharmaceuticals Inc
Futura Medical Plc
Grunenthal GmbH
GSK plc
Levicept Ltd
Neumentum Inc
Novartis AG
Olatec Therapeutics LLC
OliPass Corporation
Overseas Pharmaceuticals Ltd
Pacira BioSciences Inc
Paradigm Biopharmaceuticals Ltd
Peptide Logic LLC
Pfizer Inc
Pharmnovo AB
Pike Therapeutics Inc
Propella Therapeutics Inc
ProteoThera Inc
Pure Green Pharmaceuticals Inc
Q-State Biosciences Inc
RaQualia Pharma Inc
Regeneron Pharmaceuticals Inc
RHNanopharmacuticals LLC
Rottapharm Biotech Srl
Sansho Co Ltd
Saol Therapeutics Inc
Shanghai Leado Pharmaceutical Technology Co Ltd
Shionogi & Co Ltd
Shulov Innovative Science Ltd
Sorrento Therapeutics Inc
Symic Bio Inc
Techfields Pharma Co Ltd
Tris Pharma Inc
Vertex Pharmaceuticals Inc
Virpax Pharmaceuticals Inc
Xalud Therapeutics Inc
Xgene Pharmaceutical Inc
Xintela AB
Yooyoung Pharm Co Ltd
Zhejiang Yatai Pharmaceutical Co Ltd
ZYUS Life Sciences Inc
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Central Nervous System reports

